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Objective: To identify shared polygenic risk and causal associations in amyotrophic lateral sclerosis (ALS).
Methods: Linkage disequilibrium score regression and Mendelian randomization were applied in a large-scale, data-
driven manner to explore genetic correlations and causal relationships between >700 phenotypic traits and ALS. Expo-
sures consisted of publicly available genome-wide association studies (GWASes) summary statistics from MR Base and
LD-hub. The outcome data came from the recently published ALS GWAS involving 20,806 cases and 59,804 controls.
Multivariate analyses, genetic risk proﬁling, and Bayesian colocalization analyses were also performed.
Results: We have shown, by linkage disequilibrium score regression, that ALS shares polygenic risk genetic factors with
a number of traits and conditions, including positive correlations with smoking status and moderate levels of physical
activity, and negative correlations with higher cognitive performance, higher educational attainment, and light levels of
physical activity. Using Mendelian randomization, we found evidence that hyperlipidemia is a causal risk factor for ALS
and localized putative functional signals within loci of interest.
Interpretation: Here, we have developed a public resource (https://lng-nia.shinyapps.io/mrshiny) which we hope will
become a valuable tool for the ALS community, and that will be expanded and updated as new data become available.
Shared polygenic risk exists between ALS and educational attainment, physical activity, smoking, and tenseness/
restlessness. We also found evidence that elevated low-desnity lipoprotein cholesterol is a causal risk factor for ALS.
Future randomized controlled trials should be considered as a proof of causality.
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Amyotrophic lateral sclerosis (ALS; OMIM #105400)is a progressive, fatal neurodegenerative disease. Symp-
tom onset of ALS peaks in the mid-sixties, and most patients
succumb to the disease within 2 to 5 years of becoming symp-
tomatic.1 Prevalence of ALS is projected to nearly double by
2040, primarily attributed to aging of the global population.2
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.25431
Received Oct 5, 2018, and in revised form Feb 1, 2019. Accepted for publication Feb 1, 2019.
Address correspondence to Dr Bryan J. Traynor, Porter Neuroscience Center, 35 Convent Drive, Room 1A-213, Bethesda, MD 20892, USA.
E-mail: traynorb@mail.nih.gov
*These authors made an equal contribution.
From the 1Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD; 2Instituto
de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; 3Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen
Mary University of London, London, United Kingdom; 4Department of Clinical and Movement Neurosciences, University College London, Institute of
Neurology, London, United Kingdom; 5MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom; 6Neuromuscular Diseases
Research Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD; 7‘Rita Levi Montalcini’
Department of Neuroscience, University of Turin, Turin, Italy; 8ALS Center, Istituti Clinici Scientiﬁci Maugeri, IRCCS, Milan, Italy; 9Department of
Neurology, Helsinki University Hospital and Molecular Neurology Programme, Biomedicum, University of Helsinki, Helsinki, Finland; 10Genetics and
Pharmacogenomics, Merck Research Laboratories, Merck & Co., Inc., West Point, PA; 11Data Tecnica International, Glen Echo, MD; 12Institute of Cognitive
Sciences and Technologies, C.N.R, Rome, Italy; 13Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy; and 14Department of
Neurology, Johns Hopkins University, Baltimore, MD
Additional supporting information can be found in the online version of this article.
© 2019 American Neurological Association470
© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.470
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited.
Despite considerable advances made in understanding
the genetic architecture underlying ALS,3,4 the contribution
of lifestyle factors and of disease-related conditions predis-
posing individuals to the disorder have been more difﬁcult
to elucidate. Epidemiological studies have attempted to
identify risk factors and comorbidities associated with ALS,
although the inability of such observational research to fully
mitigate confounding effects or exclude reverse causality has
made it challenging to ﬁnd replicable causes of the disease.5
Genome-wide association studies (GWAS) have rev-
olutionized human genetics and have led to the discovery
of thousands of risk variants involved in disease etiology.6
From the perspective of ALS research, summary statistics
from hundreds of these studies have been published online
in an effort to facilitate the application of current genera-
tion genomic techniques, such as linkage disequilibrium
(LD) score regression testing and Mendelian randomiza-
tion. Both methodologies are powerful tools to assess cau-
sality and investigate the extent to which genetic etiologies
are shared across different diseases.
LD score regression and Mendelian randomization
test distinct aspects of the genetic architecture underlying a
disease. More speciﬁcally, LD score regression investigates
whether polygenic risk contributing to a phenotype of
interest might also contribute to the risk of ALS. This
approach relies on the identiﬁcation of shared genome-wide
heritability to pinpoint overlapping polygenic genetic varia-
tion between traits (pleiotropic relationship).7 On the other
hand, Mendelian randomization uses genetic data to assess
whether an exposure exerts a causal effect on a particular
outcome.8 In contrast to LD score regression, Mendelian
randomization usually focuses on genome-wide signiﬁcant
single-nucleotide polymorphisms (SNPs) for the exposure
of interest (causal relationship).8 Because this analytical
technique relies solely on genetic elements that remain
constant over the life span of an individual, and that are
randomized during gametogenesis, it effectively excludes
reverse causality and reduces confounding to allow more
reliable identiﬁcation of a causal association between expo-
sure and outcome.
Recent ALS-related Mendelian randomization studies
have focused on a hypothesis driven by only a single
trait.9–11 Here, we implemented LD score regression and
Mendelian randomization in a large-scale audit relevant to
ALS. In brief, our goal was to survey curated libraries of
GWAS results using LD score regression and Mendelian ran-
domization. The former is more liberal in identifying shared
variation that suggests a signiﬁcant degree of shared genetic
risk, whereas the latter is more conservative and attempts
to pinpoint causal associations by established loci. We also
created an online resource (https://lng-nia.shinyapps.io/
mrshiny) that can be used by the ALS community to
inform pleiotropy or causality when undertaking observa-
tional studies or pursuing disease-modifying interventions.
Materials and Methods
Outcome Data
Summary statistics from our recently published GWAS of ALS
involving 20,806 cases and 59,804 controls of European ancestry
were used as the outcome for both LD score regression and Men-
delian randomization analyses. This study included 10,031,630
genotyped and imputed variants. Sample recruitment and geno-
typing quality-control procedures are described elsewhere.4
LD Score Regression
LD patterns across the genome enable the calculation of genetic
correlations between traits. This is because the observed associa-
tion for an SNP is a product of both its own contribution toward
a phenotype and the association of the SNPs that are in LD with
it. SNPs in regions of high LD tag a greater proportion of the
genome and will show stronger associations than SNPs in regions
of low LD. Using the known LD structure of a reference SNP
panel, the heritability of a single phenotype or the genetic correla-
tion of two phenotypes can be computed using LD score
regression.7,12
To study shared genetic risk by LD score regression, we
used LD Hub, a centralized database of summary-level GWAS
results across multiple diseases/traits gathered from publicly avail-
able resources.13 LD score regression was implemented by regres-
sion of the chi-squared statistics for the genetic associations with
the trait against the LD scores for genetic variants across the whole
genome. Unlike Mendelian randomization, LD score regression
does not assess casualty, but rather only assesses multidirectional
correlations, and can distinguish between population stratiﬁcation
and polygenicity in GWAS studies. Default settings were used in
our analyses.
Mendelian Randomization
Mendelian randomization is a proxy-based approach for exploring
whether an exposure is causally associated with an outcome. This
is done by: identifying the SNPs associated with a particular expo-
sure (eg, SNPs identiﬁed in a GWAS as being associated with
colon cancer); extracting data for those SNPs from the outcome
(in this case, a large-scale GWAS of ALS4); harmonizing the expo-
sure and outcome summary data; and applying Mendelian ran-
domization methods to test for a causal relationship between the
exposure and the outcome rooted in genetic associations.
Similar to LD-Hub, the MR Base database is a curated
database containing summary results from 1,094 GWASes
involving 889 traits.14 These traits encompass a wide range of
physiological characteristics and disease phenotypes. Each trait
was tested separately as an exposure to determine if it alters risk
of developing ALS. The analyses were performed using the R
package TwoSampleMR (version 3.2.2; R Foundation for Statisti-
cal Computing, Vienna, Austria). The instrumental variables
used for each exposure/phenotype consisted of the per-allele
log-odds ratio (ie, beta estimate) and standard errors for all
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independent loci (ie, SNPs) reaching genome-wide signiﬁcance in
the tested GWAS. Of the 1,094 GWASes with data available in
MR Base (accessed August 15, 2018), 635 GWASes (consisting of
345 published GWASes and 290 unpublished GWASes performed
on the UK Biobank; www.ukbiobank.ac.uk) were included in our
analysis based on the following criteria: (1) GWAS with at least two
associated SNPs with p values <5.0 × 10–8, considering this p value
to be the generally accepted genome-wide signiﬁcant threshold;
(2) SNPs present in both the exposure and outcome (ALS) data sets
or when not present their LD proxies (R2 value > = 0.8); and
(3) independent SNPs (R2 <0.001 with any other associated SNP
within 10 Mb), considered as the most stringent clumping thresh-
old used when performing Mendelian randomization analyses.
Harmonization was undertaken to rule out strand mis-
matches and ensure alignment of SNP effect sizes. Within each
exposure GWAS, Wald ratios were calculated for each extracted
SNP by dividing the per-allele log-odds ratio of that variant in
the ALS data by the log-odds ratio of the same variant in the
exposure data. We then applied a two-step approach designed to
decrease the risk of false-positive associations (see Fig 1 for the
workﬂow).
First, the inverse-variance weighted method was imple-
mented to examine the relationship between the exposure and
ALS. In this method, the Wald ratio for each SNP is weighted
according to the inverse variance, and a line, constrained to pass
through the origin, is ﬁtted to the data. The slope of the line
represents the pooled-effect estimate of the Wald ratios.15 Traits
were brought forward to the next stage of analysis only if the
p value of the pooled-effect estimate was ≤0.05. Next, two Men-
delian randomization sensitivity tests (ie, MR Egger and weighted
median) were applied to those traits/GWASes passing the ﬁrst
phase of analysis. These sensitivity analyses evaluated core assump-
tions of Mendelian randomization, and traits were considered to
be consistent with a causal effect when p values were ≤0.05. Het-
erogeneity of effects were tested using the Cochran’s Q test, quan-
tiﬁed using the I2 statistic, and displayed in forest plots. Steiger
analyses were performed to verify that the proposed instruments
were directly associated with the outcome16 or effect estimate
directionality.
We evaluated the possibility that the overall estimate was
driven by a single SNP using leave-one-out analyses for each
of the GWASes associated with ALS. We further explored the
possibility of reverse causality by using SNPs tagging the ﬁve
independent loci described in the ALS GWAS as exposure
instrument variables and the identiﬁed GWASes as the outcome.
Lasso-based multivariate analysis was used to explore how each
related exposure of interest (ie, low-density lipoprotein [LDL]
cholesterol, self-reported cholesterol, and coronary heart disease)
independently contribute to ALS.
Genetic Risk Score
To further test the relationship between LDL cholesterol and
ALS, a cumulative genetic risk score for LDL cholesterol was calcu-
lated in a smaller subset of the samples for which individual geno-
type data were available, including 8,229 ALS cases and 36,329
controls.4 Instrumental variables of interest were incorporated and
weighted by beta values in the ALS GWAS. Next, a logistic regres-
sion was performed on this subset of cases and controls, regressing
disease against quintile membership based on genetic risk score.17
Odds ratios were reported comparing the lowest risk quintile
(reference group) to the remaining quintiles. Genetic risk scores
were also calculated for different subtypes of ALS patients (carriers
of the pathogenic C9orf72 repeat expansion, familial cases, sporadic
cases, male cases, and female cases). Risk proﬁling was adjusted for
sex, age, and 20 principal components to account for population
stratiﬁcation.
Colocalization Analysis
Bayesian colocalization analysis was used as a statistical method
to identify putative candidate genetic variants involved in LDL
cholesterol blood levels that contribute most to the risk of devel-
oping ALS.18 For these analyses, we considered the 78 SNPs that
were signiﬁcantly associated with increased LDL cholesterol and
were used as relevant instrumental variables for Mendelian ran-
domization analyses. We extracted summary statistics for those
variants (as well as variants 1 megabase [Mb] upstream and
downstream) from the LDL cholesterol GWAS and from the
ALS GWAS. Bayesian colocalization was then run for each inde-
pendent region as implemented in the R package coloc (https://
CRAN.R-project.org/package=coloc). This analysis assessed the
probability of each SNP being responsible for the change in ALS
risk through variation in LDL cholesterol. We derived posterior
probabilities (PPH0-4) for each region and considered PPH4 >
0.95 as strong evidence for colocalization under the assumption
of a single causative variant per locus.
Results
Large-Scale LD Score Regression Analysis in ALS
LD score regression was applied to examine the genetic
correlation between our recently published GWAS meta-
analysis of ALS4 and 736 phenotypes available in LD-hub,
a centralized database of GWAS results across multiple dis-
eases and traits (http://ldsc.broadinstitute.org/ldhub/; Fig 1).
Traits Genetically Correlated to ALS by LD Score
Regression
Our analyses identiﬁed 18 traits that were genetically cor-
related to ALS after adjusting for multiple testing by false
discovery rate (Table 1). Among these, nine traits were
related to educational attainment and intelligence, indicat-
ing that higher levels of education were associated with a
decreased risk of ALS (smallest adjusted p value = 1.78 ×
10–4; regression coefﬁcient = –0.338; 95% conﬁdence
interval [CI] = –0.46, –0.20).
Traits related to light physical activity, including walk-
ing for pleasure, walking as a mean of transport, and light
DIY physical activities, were associated with decreased risk
of developing ALS (smallest adjusted p value = 5.19 × 10–4;
regression coefﬁcient = –0.403; 95% CI = –0.35, –0.14),
whereas heavier activity levels such as duration of moderate
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FIGURE 1: Flow chart of analysis. The ALS Research Resource is an interactive tool where the user can explore genetic
correlations and causal associations across more than 700 traits. GWAS exposures used for LD score regressions are available in
LD hub at http://ldsc.broadinstitute.org/ldhub/. GWAS exposures used for the Mendelian randomization analyses are available in
MR Base at http://www.mrbase.org/. (A) The inclusion criteria used for LD score regression analyses comprise traits with herita-
bility estimates within normal boundaries. (B) The inclusion criteria used for Mendelian randomization includes (1) GWAS with at
least two associated SNPs with p values <5.0 × 10–8; (2) SNPs present in both the exposure and outcome (ALS) data sets or when
not present their linkage-disequilibrium (LD) proxies (R2 value > = 0.8); and (3) independent SNPs (R2 < 0.001 with any other
associated SNP within 10 Mb), considered as the most stringent clumping threshold used when performing MR analyses. (C) LD
score regression analyses included 751 publicly available GWASes considered as exposures of interest versus the most recent
ALS GWAS as an outcome, and (D) MR analyses were performed considering two phases. Phase I includes 345 available GWASes
in the public domain as exposures of interest while phase II includes unpublished UK Biobank GWAS data. (E) Signiﬁcantly associ-
ated GWASes with ALS at inverse variance weighted (p < 0.05). (F) Signiﬁcantly associated GWASes with ALS at weighted
median and MR Egger (p < 0.05). (G) Causally linked GWASes with ALS after performing reverse causality, sensitivity, and direc-
tionality analyses. (H) Multivariate analyses used to explore how each related exposure of interest independently contributes to
ALS. ALS = amyotrophic lateral sclerosis; GWAS = genome-wide association study; kb = kilobases; R2 = clumping threshold;
LDL = low-density lipoprotein.
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TABLE 1. Linkage Disequilibrium Score Regression Results for Traits Genetically Correlated With ALS
Trait Source rg [se] p
FDR
p h2 [se]
Education Fluid intelligence score UKBB –0.338
[0.067]
4.74E-07 1.78E-04 0.238
[0.011]
Qualiﬁcations: Other professional qualiﬁcations
eg: nursing_ teaching
UKBB –0.257
[0.071]
3.00E-04 1.73E-02 0.047
[0.003]
Qualiﬁcations:
A levels/AS levels or equivalent
UKBB –0.255
[0.059]
1.61E-05 1.66E-03 0.097
[0.004]
Qualiﬁcations:
college or university degree
UKBB –0.249
[0.053]
2.77E-06 5.19E-04 0.168
[0.005]
Qualiﬁcations:
O levels/GCSEs or equivalent
UKBB –0.238
[0.069]
5.00E-04 2.68E-02 0.049
[0.003]
Age completed full-time education UKBB –0.229
[0.068]
7.00E-04 3.09E-02 0.084
[0.005]
Years of schooling 2016 27225129 –0.226
[0.059]
1.00E-04 6.83E-03 0.127
[0.004]
No. of incorrect matches in round UKBB 0.229
[0.06]
1.00E-04 6.83E-03 0.055
[0.003]
Qualiﬁcations: none of the above UKBB 0.255
[0.059]
1.49E-05 1.66E-03 0.098
[0.004]
Activity Types of transport used (excluding work):
walk
UKBB –0.403
[0.085]
2.11E-06 5.19E-04 0.033
[0.002]
Types of transport used ( excluding work):
public transport
UKBB –0.402
[0.092]
1.13E-05 1.66E-03 0.022
[0.002]
Types of physical activity in last 4 weeks:
light DIY
UKBB –0.287
[0.07]
4.24E-05 3.54E-03 0.039
[0.002]
Types of physical activity in last 4 weeks:
walking for pleasure
UKBB –0.286
[0.079]
3.00E-04 1.73E-02 0.037
[0.002]
Duration of moderate activity UKBB 0.283
[0.084]
7.00E-04 3.09E-02 0.032
[0.002]
Job involves mainly walking or standing UKBB 0.216
[0.065]
9.00E-04 3.56E-02 0.08
[0.004]
Smoking Exposure to tobacco smoke at home UKBB 0.42
[0.122]
6.00E-04 3.00E-02 0.012
[0.002]
Light smokers (at least 100 smokes in
lifetime)
UKBB 0.427
[0.1]
1.77E-05 1.66E-03 0.077
[0.008]
Other Frequency of tenseness/restlessness in last 2 weeks UKBB 0.227
[0.068]
9.00E-04 3.56E-02 0.044
[0.003]
See supplementary materials for a description of the phenotypes included in the UK Biobank data set and Figure 1 for the number of traits screened as
part of the LD score regression analysis. Source: number denotes PubMed identiﬁcation numbers.
UKBB = UK Biobank; rg = regression; se = standard error; FDR = false discovery rate adjusted p value; h2 = observed narrow-sense heritability.
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activity and performing a job that involves mainly walking
or standing were positively associated to ALS (smallest
adjusted p value = 3.09 × 10–2; regression coefﬁcient =
0.28; 95% CI = –0.36, –0.09).
Smoking behavior, including exposure to tobacco and
being a light smoker, showed genetic correlation with ALS
(smallest adjusted p value = 1.66 × 10–3; regression coefﬁ-
cient = 0.42; 95% CI = 0.23, 0.62). Detailed results for the
remaining 718 nonsigniﬁcant traits are shown in Table S1
and can be interactively searched at https://lng-nia.shinyapps.
io/mrshiny.
Large-Scale Mendelian Randomization in ALS
Next, we performed Mendelian randomization to fur-
ther investigate causal links between multiple pheno-
typic traits (exposures) and ALS (outcome, Fig 1). The
exposures of interest consisted of 345 GWASes involv-
ing a wide range of physiological characteristics and
disease phenotypes for which data were available in MR
Base (http://www.mrbase.org/). The recently published
GWAS of ALS involving 20,806 cases and 59,804 con-
trols was used as the outcome.4
There are no previous reports in the literature where
multiple phenotypes were tested using Mendelian randomi-
zation in an unbiased, hypothesis-free manner. This raised
concerns about false-positive associations and multiple-
testing correction. To control for this and conﬁrm the
validity of our ﬁndings, we replicated in an independent col-
lection of phenotypes (290 unpublished GWASes per-
formed on the UK Biobank, www.ukbiobank.ac.uk). Here,
we only report associations that were signiﬁcant across both
the published and unpublished sets of GWASes. Detailed
results for the 635 GWAS under study are shown in
Tables S2 to S4 and can be visually explored at https://lng-
nia.shinyapps.io/mrshiny.
Traits Causally Linked to ALS by Mendelian
Randomization
We identiﬁed the phenotypic traits LDL cholesterol and
coronary heart disease in the published GWASes, and self-
reported high cholesterol in the UK Biobank, as being caus-
ally linked to ALS risk (see Table 2 and Table S5 for SNPs
used to construct the instruments of interest. Multivariate
analysis showed that the signals arising from the coronary
heart disease and self-reported high cholesterol were driven
by SNPs related to LDL cholesterol, revealing that both
traits represent closely related phenotypes (Table 3).
Leave-one-out analysis indicated that no single SNP
accounted for these associations in isolation (Table S6).
Additional analyses examining directionality, pleiotropy,
and reverse causality did not indicate any violation of core
Mendelian randomization assumptions for these traits
(Tables S7–S8). We used genetic risk proﬁling to estimate
the extent to which risk of developing ALS is attributable
to LDL cholesterol. We found that individuals with the
highest burden of genetic risk were 1.075 times more
likely to develop ALS (95% CI, 1.001–1.150; p value =
0.003). The increase in ALS risk associated with LDL
cholesterol levels was similar across different subtypes of
ALS (C9orf72 carriers, familial ALS, sporadic ALS, male,
and female-only cases; Table S9).
Identiﬁcation of Functional Causal Variants
Bayesian colocalization analysis was performed to puta-
tively identify the functional candidate variants that may
drive risk of developing ALS through shared pathway
effects of LDL cholesterol levels. We focused our efforts
TABLE 2. Mendelian Randomization Results for Exposures Causally Linked to ALS
Inverse Variance
Weighted MR Egger Weighted Median
Exposure Source
No. of
SNPs
OR
[CI 95%] p
OR
[CI 95%] p
OR
[CI 95%] p
LDL cholesterol
id:300
24097068 78 1.116
[1.03–1.20]
0003 1.115
[1.00–1.23]
0054 1.108
[1.00–1.226]
0046
Coronary heart
disease id:7
26343387 37 1.063
[1.0–1.13]
0047 1.175
[1.01–1.35]
0032 1.116
[1.020–1.220]
0015
Self-reported:
high cholesterol
id:UKB-a:108
UKBB 49 2.389
[1.48–3.84]
00003 2.669
[1.08–6.55]
0038 2.110
[1.021–4.357]
0044
id = speciﬁc code attributed to each trait by MR Base; No. of SNPs = number of SNPs; OR = odds ratio; CI = conﬁdence interval; LDL = low-
densitity lipoprotein.
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on the 78 independent regions associated with LDL cho-
lesterol in the exposure GWAS. This analysis identiﬁed
two independent regions with >95% probability of con-
taining a shared causal SNP (Table S10). Fine mapping of
these regions identiﬁed two SNPs (rs182826525 within
COL4A3BP and rs116226146 intergenic between PPP1R2P3
and TIMD4) as being causally linked to ALS through an
increase of LDL cholesterol levels (Fig 2).
Discussion
We applied cutting-edge analytical techniques to genomic
data across a wide range of phenotypic traits to identify
factors associated with risk of developing ALS. This
hypothesis-free, data-driven approach provided prima facie
evidence supporting the existence of multiple such factors.
Using genetic data to comprehensively map the risk factor
landscape of ALS represents a novel approach in neurolog-
ical disease. We used these results from nearly 25 million
individuals (24,538,000 from published GWAS and
337,159 from UKBB studies) to establish a public resource
that can be accessed by other researchers to explore risk
factors and shared disease mechanisms in ALS.
LD score regression analyses found that common
genetic variation associated with higher cognitive perfor-
mance is negatively correlated to ALS. At a molecular level,
these ﬁndings indicate that the genetic factors driving men-
tal ability and ALS overlap to some extent. This may have
been an expected outcome given the well-known relation-
ship between ALS and frontotemporal dementia, and our ﬁnd-
ings are consistent with previous epidemiological reports
assessing the causal relationship between education and
ALS.19 Nevertheless, the large number of samples ana-
lyzed in our study and its grounding in genetics put this
risk factor on a ﬁrmer footing within the ALS ﬁeld.
Similar education effects have been observed in Alzheimer’s
disease,20 but understanding how education protects
against neurodegeneration or which genetic variants are
responsible for this shared risk will require additional
study. One intriguing possibility is that the genetic vari-
ants responsible for ALS in middle age or in the elderly
are also associated with decreased cognitive performance
at a younger age. This is plausibly consistent with the
observation that connectivity and gray matter volumes
are altered in asymptomatic carriers of the C9orf72 repeat
expansion.21,22
Epidemiological case-control studies have extensively
reported a relationship between exercise and risk of develop-
ing ALS,23–25 though there are conﬂicting results as to the
level of physical activity required to increase risk.19 Our
genetic-based data demonstrate that this neuromuscular
interconnection may be more complex than previously
appreciated: Light physical activity, including walking for
pleasure or light DYI activities, was negatively associated with
developing ALS, whereas more strenuous activity, such as
duration of moderate activity, was paradoxically correlated
with ALS. Extrapolating from these observations to neuro-
muscular physiology, relatively low levels of exercise may
exert a neuroprotective effect by preventing muscle atrophy
that, in turn, supports motor neuron integrity though the
neuroadaptive generation of neurotrophic factors.26 In con-
trast, excessive physical activity may be detrimental to motor
neurons because of excessive free radical production and/or
glutamate excitotoxicity that overwhelms neuroprotective
mechanisms.27,28 Regardless, our data do not provide any
insight into the effect of exercise on survival once the patient
has presented with symptoms.
There is compelling epidemiological evidence show-
ing that cigarette smoking is a key environmental risk fac-
tor for ALS.29 Our LD data not only conﬁrm that being a
TABLE 3. Multivariable Analysis to Estimate the Simultaneous Effects of Two Exposures
a) Analysis comparing LDL cholesterol vs self-reported cholesterol
Exposure No. of SNPs beta se p
LDL cholesterol || id:300 72 0175 0084 0019
Self-reported high cholesterol || id:UKB-a:108 34 –0847 0722 0120
b) Analysis comparing LDL cholesterol vs coronary heart disease
Exposure No. of SNPs beta se p
LDL cholesterol || id:300 74 0087 0040 0014
Coronary heart disease || id:7 26 0027 0038 0239
id = speciﬁc code attributed to each trait by MR Base; se = standard error; No. of SNPs = number of SNPs; LDL = low-density lipoprotein.
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smoker is positively correlated to developing ALS, but also
show that this effect is mediated, at least in part, through
shared genetic mechanisms. This is an example of the abil-
ity of this type of genomic analysis to identify pleiotropic
effects, which is where a defect in a single gene can give
rise to multiple, apparently unrelated phenotypes. Here,
we are extending the concept of pleiotropy beyond the
single-gene paradigm to encompass inherently complex
traits driven by multiple genetic variants spread across the
genome and that are typically outside of coding regions.
LD score regression is not designed to identify the speciﬁc
shared genetic variants responsible for both phenotypic
traits, but instead focuses on establishing whether such
pleiotropy exists between traits.
FIGURE 2: Bayesian colocalization plots. A plot and B plot represent two independent LDL-cholesterol–associated regions with
posterior probability greater than 95% of sharing a causal variant involved in ALS. Panels in column A show the region spanning
chr5:73656720-75651786 where rs182826525 is likely the shared causal variant with a posterior probability of nearly 100%. Panels
in column B show the region spanning chr5:155390511-157388284 where rs116226146 is likely the shared causal variant with a
posterior probability of 96%. The ﬁrst row displays the p values from the LDL GWAS for each region. Color is coded by p values in
the ALS GWAS. The second row displays the p values from the ALS GWAS for the same regions. Color is coded by p values in the
LDL GWAS. The third row shows local gene positions (with strands denoted by ), as well as recombination rates measured in
cM/Mb.38 The bottom row shows the posterior probabilities of a shared causal variant between LDL cholesterol and ALS.
ALS = amyotrophic lateral sclerosis; GWAS = genome-wide association study; kb = kilobases; LDL = low-density lipoprotein.
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Using Mendelian randomization, we found strong
evidence that an alteration of lipid metabolism is causally
linked to ALS. We undertook sensitivity analyses to
reduce the possibility of bias in our results and replicated
our ﬁndings across three different exposure GWASes,
including a large, independent cohort obtained from the
UK Biobank. Furthermore, we demonstrated that the
increased risk of ALS attributed to coronary heart disease
is driven by LDL cholesterol. Though hyperlipidemia only
modestly increases the risk of ALS, this effect likely oper-
ates over the lifetime of the individual, and the cumulative
effect on disease risk may be substantial.
Previous epidemiological studies have explored the role
of blood lipids in the pathogenesis of ALS. These observa-
tional studies have yielded controversial results, with many
reporting that hyperlipidemia increases disease risk and
others suggesting the opposite.30–36 In addition to being
underpowered, much of this previous research was based on
blood-lipid proﬁles obtained after diagnosis of ALS when
ancillary factors may be inﬂuencing these levels.30–36
The singular advantage of Mendelian randomization
is that it is agnostic to these confounders and can be con-
sidered nature’s randomized controlled trial. Based on
genetic data that remain constant between the presympto-
matic and symptomatic phases of the disease, it accurately
pinpoints predisposing factors for the disease of interest.
While the manuscript for this article was under review, a
link between blood lipids and the risk of ALS has been
recently reported in European and East Asian populations
using polygenic risk scores and Mendelian randomiza-
tion.9,10 These studies were performed involving a smaller
cohort of ALS cases and were based on the a priori hypoth-
esis that blood lipids were involved in the pathogenesis of
ALS. Our work extends these recent reports by deﬁnitely
applying Mendelian randomization across a large number
of phenotypic traits in an unbiased fashion, replicating our
ﬁndings in an independent cohort (UK Biobank), and
delineating the speciﬁc aspects of lipid metabolism relevant
to the pathogenesis of ALS.
Circulating blood cholesterol are multifunctional
molecules, involved primarily in energy generation, as pre-
cursors or cofactors for signaling molecules, and in neuro-
nal development and function.37 Dysregulation of
cholesterol homeostasis in the brain has been linked to
many neurodegenerative diseases such as Huntington’s
disease, Parkinson’s disease, Niemann-Pick disease type C,
and, most notably, Alzheimer’s disease.38 The generation
and clearance of β-amyloid protein is regulated by choles-
terol, and drugs that inhibit cholesterol synthesis lower
this protein within neurons,39 as is the more recent ﬁnding
that the two secretory forms (APPɑ and APP β) of amyloid
precursor protein (APP) have opposing associations with
β-amyloid generation, cholesterol biosynthesis, and LDL
receptor levels.40 The identiﬁcation of the cholesterol trans-
port protein, apolipoprotein E, as a major genetic risk factor
for Alzheimer’s disease is also consistent with a role for cho-
lesterol in the pathogenesis of neurodegenerative dis-
ease.41,42 Despite this, the molecular mechanisms by which
altered lipid metabolism leads to neuron degeneration are
unclear.
An important question arising from our analysis cen-
ters on why LDL may causally affect ALS, while at the
same time LDL levels are not genetically correlated with
ALS under the LD Score regression model. This apparent
divergence is because the variants linked to these two traits
are not pleiotropic, and again highlights the fact that Men-
delian randomization and LD regression analysis investigate
different aspects of the genetic architecture underlying dis-
eases. Mendelian randomization allows us to compare two
groups of people that differ by the genetic variants of inter-
est and therefore by any modiﬁable factor to which those
genetic variants relate. In this case, genetic variants that are
associated with LDL metabolism affect LDL levels, and a
ratio measure is calculated to determine how much this
estimated change in LDL level would predispose individuals
to ALS. If substantial pleiotropy were present, we would
ﬁnd that the same genetic variants that affect LDL metabo-
lism also increase the risk of ALS by themselves (ie, genetic
correlation). Such pleiotropy was not observed in our data.
Instead, we found that the only mechanism by which ALS
risk could be increased is through an increase of LDL cho-
lesterol levels (ie, linear association).
Our data led us to propose that lowering blood-
cholesterol levels is a viable strategy for reducing risk associ-
ated with ALS. A similar approach may be effective in
Alzheimer’s disease where exposure to statins is associated
with substantially reduced risk of dementia in observational
studies.43,44 Though the American Heart Association guide-
lines for treating blood cholesterol to reduce cardiovascular
risk are widely implemented in the community, they pri-
marily focus on patients aged >50 years.45 An alternative
strategy may be to identify a younger subpopulation at
increased risk of developing ALS and institute treatment
with lipid-lowering agents. This approach would initially
focus on individuals with a family history of ALS or fronto-
temporal dementia, and on presymptomatic cases carrying
the C9orf72 repeat expansion; together, these subtypes
account for nearly 1 in 5 cases of ALS.46 Long-term monitor-
ing would be required to detect side effects from the medica-
tion and determine effect on age of disease onset.
We conclude by saying that the reported ﬁndings
should be interpreted in the context of existing evidence
from other research studies using different designs, and
deﬁnite conclusions should not be elaborated uniquely
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based on Mendelian randomization results. Future ran-
domized controlled trials should be considered as a proof
of causality.
Limitations to This Study
Our analyses were limited to only those GWAS studies pre-
sent in two public databases, namely LD-hub and MR Base.
Furthermore, the available data are focused on European
populations. We envisage that future studies may expand
our ﬁndings by utilizing larger sample sizes, greater density
across the genome, and importantly non-European popula-
tions, highlighting the utility of an ALS resource that is
constantly updated as new data become available.
One of the main caveats of working with summary
level data (rather than individual-level data) is that there is
no possibility to ﬁlter and exclude sample overlap. For
Mendelian randomization analyses, we cannot exclude the
possibility that samples from the same individuals were used
in both the GWASes that we identiﬁed as signiﬁcant expo-
sures and in the ALS GWAS that we used as the outcome
measure. Such sample overlap may bias estimates in MR
and increase type 1 error rates. We reviewed the origin of
the European cohorts present in our ALS outcome and in
the signiﬁcantly associated exposures, and the results of this
comparison are outlined in Table S11. Our data suggest
that sample overlap had only a minimal effect on our
results. We also performed sensitivity analyses by calculat-
ing the F-statistic parameter as described elsewhere.47 Our
results showed that two of the three GWASes of interest
for which the F-statistic could be calculated were considered
strong instruments and are unlikely to be susceptible to bias
because of overlapping samples (F-statistic for LDL choles-
terol = 59.02; F-statistic for coronary heart disease = 742.2).
Furthermore, sample overlap alone cannot account for our
ﬁndings, given that any sample overlap would be equally
likely to occur across the diverse GWASes that we studied,
and yet we consistently identiﬁed altered lipid metabolism
as a risk factor for ALS across multiple GWAS studies and
across multiple populations. There is no realistic scenario
in which sample overlap could have been consistently con-
ﬁned to just GWASes involving lipid metabolism. How-
ever, given that Mendelian randomization effect estimates
are often small, mandating additional follow-up on con-
nected pathways.
A concern that might arise is to what extent heredi-
tary cases of ALS carrying rare genetic variants might have
inﬂuenced our analyses. One should expect that carrying
large effect, rarer variants would not generally preclude
the carrying of more common, small effect genetic risk
factors which comprise the majority of GWAS results that
were used for Mendelian randomization and LD Score
regressions.
Finally, we are aware that certain bias could exists
because of undetectable issues in underlying GWAS
results utilized in this survey, but the fact that we have
replicated our results in independent GWASes alleviates
this concern.
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